End-to-end DNA sequencing solution with Exatype and Roche

Exatype supports the automated analysis of data generated from Roche’s KAPA HyperCap SARS-CoV-2 panel and Roche’s KAPA HyperPETE Panel for HIV

Hyrax Biosciences and Roche have partnered to enable integrated sample prep to reporting workflows for sequencing-based testing and research.

Pairing Hyrax Biosciences' Exatype platform with Roche's KAPA HyperCap and KAPA HyperPETE workflows provides integrated, end-to-end solutions from sample prep through to data analysis, interpretation and reporting.

Exatype supports the automated analysis of data generated from Roche’s KAPA HyperCap SARS-CoV-2 Panel (RUO) thereby making sequencing for SARS-CoV-2 genomic surveillance faster, cheaper and more accurate.

Viral RNA in host RNA background

Library Prep with KAPA RNA HyperPrep Kit

Target Enrichment with KAPA HyperCap SARS-CoV-2 panel

Final library enriched with viral targets

Next Gen Sequencing

Analysis and reporting using the Exatype platform

Try our Exatype Analysis Solution for Free

Sign up at ngs.exatype.com and run your first samples for free!

/images/roche/sars-cov-2-ui-create-job.png
/images/roche/sars-cov-2-ui-results.png

Benefits of Roche Sequencing Analysis with Exatype

Exatype has been tailored for the analysis of sequence data generated using Roche’s KAPA HyperPETE Panel for HIV and Roche’s KAPA HyperCap SARS-CoV-2 panels:

Automated primer deduplication

Report variant prevalences with confidence

Customisable prevalence setting for variant detection

Harness the power of Exatype’s algorithms in detecting low abundance variants e.g. surveillance studies and detection of dual-infection

Easy to use

Intuitive drag-and-drop interface means minimal end-user input needed to analyse data

Scalability

Scale up with ease using Hyrax Biosciences’ streamlined and secure, cloud-based IT infrastructure

High quality results

Confidently detect and report variants with the Exatype platform

Minimise time

Report your findings faster by on-cloud parallel processing using the intuitive interface of the Exatype platform

Proven expertise

Hyrax Biosciences’ proven expertise in viral-sequence analysis and reporting offers reliable variant detection and surveillance

High-throughput

APIs enable direct integration with sequencers and/or LIMS (contact us for more information)

Get in touch

Further information

Brochure

Read more about the Hyrax-Roche co-promotion partnership.

Download PDF

Presentation

Learn more about streamlining your SARS-CoV-2 sequencing with the Roche’s KAPA HyperCap SARS-CoV-2 Panel (RUO) and the Exatype platform.

Download PDF

The Exatype Platform: An end-to-end Bioinformatics Software Platform

Our modular platform can analyse and interpret sequence data from an ever-expanding range of applications, including:

Genotyping and drug-resistance testing in infectious diseases e.g. HIV, TB, SARS-CoV-2.

Multi-target diagnostics, e.g. infectious disease panels.

Tumour profiling and drug-susceptibility testing in cancer.

Low abundance variant detection e.g. detecting mixed infections or the detection of biomarkers in liquid biopsies.

Your Sequence data.

One Solution.

Discover our sequence-analysis solutions